OBJECTIVES: To determine the prophylactic efficacy of an Sm-p80-based vaccine formulation against challenge infection with Schistosoma mansoni in mice using an approach comprising of initial priming with DNA and boosting with recombinant protein in the presence of resiquimod (R848) as an adjuvant. METHODS: In the first experiment (prime-boost approach), mice were primed with Sm-p80-pcDNA3 (week 0) and boosted at weeks 4 and 8 with recombinant Sm-p80 formulated in resiquimod (R848). Each mouse in the control group first received only pcDNA3 and was boosted with R848. In the second set of experiments (recombinant protein approach), mice were immunized (week 0) and boosted (weeks 4 and 8) with rSm-p80 formulated in R848. Animals of the control group in this series of experiments received only R848 at 0, 4, and 8 weeks. All of the animals from both the 'prime-boost' and 'recombinant protein' groups were challenged with cercariae of S. mansoni, 4 weeks after the last immunization. The mice were sacrificed 6 weeks post-challenge and the reductions in worm burden and egg production were determined. Sm-p80-specific antibody titers were estimated in the mice sera by ELISA. Cytokine mRNA and protein production by proliferating splenocytes in response to in vitro stimulation with Sm-p80, were estimated via RT-PCR and ELISA, respectively. RESULTS: Vaccination with Sm-p80 (prime-boost approach) showed 49% reduction in worm burden; with the recombinant protein approach the protection was found to be 50%. The protection levels were correlated with antibody production. Upon antigenic stimulation with recombinant Sm-p80, splenocytes secreted significant levels of interferon (IFN)-γ and interleukin (IL)-2, indicating that the immune responses were Th1-biased and this was further supported in terms of distribution of antibody isotypes and mRNA expression of cytokines. CONCLUSIONS: In conclusion the present study clearly demonstrates that Sm-p80 consistently maintained its protective nature, and resiquimod as an immunopotentiating agent slightly boosted the protective effects of Sm-p80 in both 'DNA prime-protein boost' and 'recombinant protein' immunization approaches in a murine model.
OBJECTIVES: To determine the prophylactic efficacy of an Sm-p80-based vaccine formulation against challenge infection with Schistosoma mansoni in mice using an approach comprising of initial priming with DNA and boosting with recombinant protein in the presence of resiquimod (R848) as an adjuvant. METHODS: In the first experiment (prime-boost approach), mice were primed with Sm-p80-pcDNA3 (week 0) and boosted at weeks 4 and 8 with recombinant Sm-p80 formulated in resiquimod (R848). Each mouse in the control group first received only pcDNA3 and was boosted with R848. In the second set of experiments (recombinant protein approach), mice were immunized (week 0) and boosted (weeks 4 and 8) with rSm-p80 formulated in R848. Animals of the control group in this series of experiments received only R848 at 0, 4, and 8 weeks. All of the animals from both the 'prime-boost' and 'recombinant protein' groups were challenged with cercariae of S. mansoni, 4 weeks after the last immunization. The mice were sacrificed 6 weeks post-challenge and the reductions in worm burden and egg production were determined. Sm-p80-specific antibody titers were estimated in the mice sera by ELISA. Cytokine mRNA and protein production by proliferating splenocytes in response to in vitro stimulation with Sm-p80, were estimated via RT-PCR and ELISA, respectively. RESULTS: Vaccination with Sm-p80 (prime-boost approach) showed 49% reduction in worm burden; with the recombinant protein approach the protection was found to be 50%. The protection levels were correlated with antibody production. Upon antigenic stimulation with recombinant Sm-p80, splenocytes secreted significant levels of interferon (IFN)-γ and interleukin (IL)-2, indicating that the immune responses were Th1-biased and this was further supported in terms of distribution of antibody isotypes and mRNA expression of cytokines. CONCLUSIONS: In conclusion the present study clearly demonstrates that Sm-p80 consistently maintained its protective nature, and resiquimod as an immunopotentiating agent slightly boosted the protective effects of Sm-p80 in both 'DNA prime-protein boost' and 'recombinant protein' immunization approaches in a murine model.
Authors: Afzal A Siddiqui; Justin R Pinkston; Martha L Quinlin; Qaiser Saeed; Gary L White; Michael H Shearer; Ronald C Kennedy Journal: Vaccine Date: 2005-02-10 Impact factor: 3.641
Authors: J K Smith; A A Siddiqui; L A Modica; R Dykes; C Simmons; J Schmidt; G A Krishnaswamy; S L Berk Journal: J Interferon Cytokine Res Date: 1999-08 Impact factor: 2.607
Authors: Akram A Da'Dara; Norman Lautsch; Timothy Dudek; Vladimir Novitsky; Tun-Hou Lee; Myron Essex; Donald A Harn Journal: Vaccine Date: 2006-04-18 Impact factor: 3.641
Authors: Afzal A Siddiqui; Troy Phillips; Hugues Charest; Ron B Podesta; Martha L Quinlin; Justin R Pinkston; Jenny D Lloyd; Janet Pompa; Rachael M Villalovos; Michelle Paz Journal: Vaccine Date: 2003-06-20 Impact factor: 3.641
Authors: Qyana Griffith; YanMei Liang; Patrick Whitworth; Carlos Rodriguez-Russo; Ahmad Gul; Afzal A Siddiqui; John Connor; Pauline Mwinzi; Lisa Ganley-Leal Journal: Exp Parasitol Date: 2015-03-24 Impact factor: 2.011
Authors: Weidong Zhang; Adebayo J Molehin; Juan U Rojo; Justin Sudduth; Pramodh K Ganapathy; Eunjee Kim; Arif J Siddiqui; Jasmin Freeborn; Souad R Sennoune; Jordan May; Samra Lazarus; Catherine Nguyen; Whitni K Redman; Gul Ahmad; Workineh Torben; Souvik Karmakar; Loc Le; Kameswara R Kottapalli; Pratibha Kottapalli; Roman F Wolf; James F Papin; David Carey; Sean A Gray; Jenn D Bergthold; Raymond T Damian; Bryan T Mayer; Florian Marks; Steven G Reed; Darrick Carter; Afzal A Siddiqui Journal: Ann N Y Acad Sci Date: 2018-08 Impact factor: 5.691
Authors: Gul Ahmad; Weidong Zhang; Workineh Torben; Afzal Ahrorov; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Pauline N M Mwinzi; Lisa Ganley-Leal; Ronald C Kennedy; Afzal A Siddiqui Journal: J Infect Dis Date: 2011-09-15 Impact factor: 5.226
Authors: Souvik Karmakar; Weidong Zhang; Gul Ahmad; Workineh Torben; Mayeen U Alam; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui Journal: Vaccine Date: 2014-01-04 Impact factor: 3.641
Authors: Adebayo J Molehin; Juan U Rojo; Sabrina Z Siddiqui; Sean A Gray; Darrick Carter; Afzal A Siddiqui Journal: Expert Rev Vaccines Date: 2016-01-13 Impact factor: 5.217